

Steve Sisolak
Governor



Richard Whitley, MS
Director

DEPARTMENT OF
HEALTH AND HUMAN SERVICES
DIVISION OF PUBLIC AND BEHAVIORAL HEALTH
Helping people. It's who we are and what we do.



Lisa Sherych
Administrator

Ihsan Azzam,
Ph.D., M.D.
Chief Medical Officer

Technical Bulletin

Date: November 3, 2022
Topic: Novavax COVID-19 Vaccine, Adjuvanted Booster Now Authorized for 18+
Contact: Jessica Lamb, RN, Nevada State Immunization Program
To: All Health Care Providers and Facilities; Pharmacists; Local Health Authorities

Background:

On October 19, 2022, the U.S Food and Drug Administration [re-issued a letter of authorization](#), in its entirety, to authorize the use of [Novavax COVID19 Vaccine, Adjuvanted](#) as a **first booster dose**. By authorizing an additional COVID-19 booster vaccine, adults in the United States who have not yet received a COVID-19 booster vaccine, now have expansion in available COVID-19 booster vaccine options. This monovalent booster vaccine contains the SARS-CoV-2 spike protein and [Matrix-M adjuvant](#). [Adjuvants](#) are ingredients used in some vaccines that help to create a stronger immune response for the vaccinated individual.

This technical bulletin summarizes the recent Novavax COVID-19 Vaccine, Adjuvanted booster eligibility recommended for individuals ages 18 years of age and older. **At this time**, Novavax COVID-19 Vaccine, Adjuvanted has been authorized as a **first** booster dose only. If an individual has received anything more than the doses required to complete their primary series, then they are **not** eligible to receive a Novavax booster. To be eligible, an individual must not have received a prior monovalent or bivalent COVID-19 booster of any brand.

This booster dose is for the following individuals, at least 6 months after completion of a primary vaccination with a FDA authorized COVID-19 vaccine (Moderna, Pfizer, Novavax or Janssen) and who have not yet received a booster of any formulation:

- Individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine (either Moderna or Pfizer) is not accessible or clinically appropriate.
- Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.

[Novavax's COVID-19 Vaccine, Adjuvanted](#) Information Fact Sheets have now been updated to reflect their new monovalent booster authorization. [Novavax's COVID-19 Vaccine, Adjuvanted](#) Information Fact Sheets have now been updated to reflect their new monovalent booster authorization. Below you will find additional information and resources for:

- Any [Recipients and/or Caregivers](#) and [Healthcare Providers](#) for those individuals 18 years of age and older.
- Storage & Handling: The same [storage and handling requirements and guidelines](#) as all other Novavax COVID-19 adjuvanted vaccines.

For more information and/or additional resources, please visit the Centers for Disease Control and Prevention (CDC)'s [COVID-19 Interim Clinical Considerations website](#).

Novavax

Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Dose	Injection volume
Primary series vaccination						
12 years and older	Monovalent	Royal blue	No color	No	5 µg rS and 50 µg of Matrix-M™ adjuvant	0.5 mL
Booster vaccination						
18 years and older	Monovalent	Royal blue	No color	No	5 µg rS and 50 µg of Matrix-M™ adjuvant	0.5 mL

It is important to note the primary goal of the COVID-19 vaccine response should continue to be COVID-19 vaccine administration to the unvaccinated. The Nevada Department of Health and Human Services is encouraging individuals to speak with a health care provider about vaccination and COVID-19 vaccines. Individuals may be referred to NVCOVIDFighter.org or 1-800-401-0946 for more information on vaccine access and other COVID-19 resources.

Questions:

For updated guidance, please review the [DPBH Technical Bulletin web page](#) and the [Nevada Health Response website](#) regularly. Email questions to dpbhcovid19vax@health.nv.gov.



Lisa Sherych, Administrator
Division of Public and Behavioral Health



Ihsan Azzam, Ph.D., M.D.
Chief Medical Officer